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Recommendation for the use of newly introduced 
Tdap vaccine in Korea
Pertussis is an acute respiratory infection characterized by paroxysmal 
cough and inspiratory whoop for over 2 weeks. The incidence of 
pertussis has decreased markedly after the introduction of DTwP/DTaP 
vaccine, but the incidence of pertussis has increased steadily among 
young infant and among adolescents and adults in many countries. Td 
vaccine was used in this age group but the increase in pertussis has 
lead to the development of a Tdap vaccine. The Tdap vaccine is a Td 
vaccine with a pertussis vaccine added and is thought to decrease the 
incidence and transmission of pertussis in the respective age group. In 
Korea, two products are approved by the KOREA FOOD & DRUG 
ADMINISTRATION, which are ADACEL
TM (Sanofi-Pasteur, Totonto, 
Ontario, Canada) and BOOSTRIX
Ⓡ (GlaxoSmithKline Biologicals, 
Rixensart, Belgium) for those aged between 11-64. This report 
summarizes the recommendations approved by the Committee on 
Infectious Diseases, the Korean Pediatric Society.
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and lack of natural booster events
5-8). The immunity against pertussis 
is maintained only for around 5-6 years after immunization
9). The 
increase of pertussis among adolescents and adults act as a source of 
pertussis for young infant before immunization with DTaP. Thus, 
it is important for adolescents and adults to maintain immunity to 
pertussis in order to decrease the incidence of pertussis in this age 
group and to protect young infant from pertussis, and Tdap vaccine 
(‘Tdap’ hereinafter) was introduced for this purpose. 
In the U.S., two products of Tdap were approved in 2005, which 
are ADACEL
TM (Sanofi-Pasteur, Totonto, Ontario, Canada) for 
those aged between 11-64 and BOOSTRIX
Ⓡ(GlaxoSmithKline 
Biologicals, Rixensart, Belgium) for those aged between 10-
64. In Korea, ADACEL
TM was approved in June 2009 and 
BOOSTRIX
Ⓡ in June 2010 by the KOREA FOOD & DRUG 
Introduction
Pertussis is an acute respiratory infection characterized by 
paroxysmal cough and inspiratory whoop for over 2 weeks. The 
incidence of pertussis has decreased markedly after the introduction 
of DTwP/DTaP vaccine (‘DTwP/DTaP’ hereinafter), but pertussis is 
still one of important infectious diseases as around 300,000 people 
are estimated to die of the disease each year throughout the world
1) 
(Fig. 1). 
The outbreak of pertussis has decreased significantly after 
immunization, but according to reports in the U.S., the incidence 
of pertussis has increased steadily among young infant and among 
adolescents and adults since the 1980s
2-4). This phenomenon is 
possibly due to the waning immunity since childhood immunization 142      KM Choi, et al. • Recommendation for the use of newly introduced Tdap vaccine in Korea
ADMINISTRATION for the prevention of diphtheria, tetanus and 
pertussis in adolescents and adults aged between 11-64.
 The purpose of this statement is to provide the rationale and 
recommendation for adolescent use of  Tdap vaccine in Korea (Box 1). 
Pathogen
Pertussis is caused by Bordetella pertussis, a fastidious Gram-
negative coccobacillus. It is one of the most highly communicable 
diseases, attack rates in susceptible household contact range from 70 
to 100 percent. The main infection reservoir is adolescents or adults 
who show a light symptom or do not show any symptom, and the 
symptom is most severe when the disease occurs in infants younger 
than 6 months who have not completed the immunization. Pertussis-
like syndrome may be caused by adenovirus type 1, 2, 3 and 5, 
Bordetella parapertussis, Chlamydia trachomatis, etc. Disease caused 




Human is the only host of pertussis. Infection occurs by a direct 
contact or by respiratory droplets from a coughing patient. The 
outbreaks of pertussis have decreased markedly with the increase of 
immunization rate throughout the world (Fig. 1), but are reported 
intermittently. Despite the high immunization rate since the 1980s, 
the incidence of pertussis increased steadily in young infants as well 
as in adolescents and adults
3, 4, 11). In particular, adolescents act as a 
reservoir and spread the disease to young infants with a high risk 
of complications
12, 13). The recent increasing number of reports on 
the occurrence of pertussis is partially the result of active diagnostic 
examination and the advance of diagnostic technology. However, 
the increase of incidence in specific age groups suggests that pertussis 
may be prevalent continuously in the future if booster vaccination 
is not performed. Although data are not sufficient on the incidence 
of pertussis in Korea, according to recent statistics from the Korea 
Center for Disease Control and Prevention (KCDC), the report of 
pertussis shows an increasing pattern, so adequate actions should be 
taken. In Korea, large-scale outbreaks of pertussis have disappeared 
with the DTwP/DTaP immunization, but small-scale ones have 
been being repeated since 1995 and around 11.5 cases are being 
reported each year on the average. However, the accurate incidence 
is unknown due to the absence of pertussis diagnosis in primary 
hospitals and sentinel surveillance system, but according to disease 
surveillance reports by the KCDC, the number of cases increased in 
2009 (Fig. 2). In addition, according to domestic data, pertussis was 
the cause of chronic cough in 2.9% of adults with chronic cough
14).
The reasons for the steady rise in the incidence of pertussis include 1) 
a genetic change in B.pertussis
15, 16), 2) the waning immunity, 3) poor 
management of adolescent and adult pertussis patients. In domestic 
studies as well, it was found from strains isolated from Korean 
pertussis patients that pertussis antigens are changing continuously 
over time
17).
Box 1. Summary of Recommendation for Use of Newly Introduced Tdap 
vaccine
1. Subjects
1) Adolescents aged 11-18 years who have completed the DTaP 
immunization series during infancy and childhood should receive a 
single dose of Tdap. It is recommended to immunize at the age of 11-
12 years. 
2) For adolescents aged 11-18 years who received Td, it is recommended 
to receive a single dose of Tdap 2 years after the Td immunization.
2. Administration and dosage
    Intramuscular injection of 0.5 mL
3. Adverse events
    Local adverse events: pain, edema and erythema, etc.
    Systemic adverse events: fever, headache and fatigue, etc.
4. Contraindications
    The same as DTaP vaccine
5. Precautions
The same as DTaP vaccine
If Guillain-Barre syndrome was observed within 6 weeks after immu-
nization containing tetanus toxoid in the past, health care professionals 
should evaluate the risk and benefits of administering Tdap or Td. 
In case of progressive neurologic disorder, delay the immunization until 
the condition has stabilized. 
Fig. 1. The number of reported cases of pertussis and DTP3 coverage, 
1980-2008.
Fig. 2. The number of reported cases of pertussis by year – South 
Korea, 2001-2009, from KCDC.Korean J Pediatr 2011;54(4):141-145 • DOI: 10.3345/kjp.2011.54.4.141    143
Clinical Manifestations 
In general, pertussis has an incubation period of 7-10 days. The 
illness has three stages (catarrhal stage, paroxysmal stage, convalescent 
stage), and infectivity is highest in the catarrhal stage and falls rapidly 
afterwards, but transmission is possible for around 3 weeks. A 
characteristic paroxysmal cough occurs mainly at night and 15 fits 
around 24 hours on the average, maintaining similar intensity for 
2-3 weeks and even up to 10 weeks. The frequency of complications 
and hospitalization is higher in infants and toddlers younger than 12 
months than in older ones
13, 18, 19). Among complications, the most 
common and fatal one is pneumonia caused by secondary bacterial 
infection. Besides, hypoxia-induced convulsion, encephalopathy, 
etc. may happen in infants, and paroxysmal cough may cause 
pneumothorax, nasal bleeding, subdural hematoma, hernia, rectal 
prolapse, etc.
Pertussis in adolescence shows considerable variation from mild to 
severe. When classic symptoms do not appear, the disease may not 
be distinguishable from other respiratory infections. Around half of 
adolescents diagnosed with pertussis cough for over 10 weeks, 72-
100% show symptoms such as paroxysmal cough, dyspnea and sleep 
disturbance, 50-70% are accompanied with vomiting, 1-2% are 
hospitalized for pneumonia, etc., and 0.2-1% show symptoms such as 
convulsion and unconsciousness
20, 21). It was found that pertussis was 
the cause of the cough in 13-20% of adolescents and adults with non-
specific cough continuing for over a week
22).
Diagnosis
Pertussis is a highly communicable disease, and if one has contacted 
a pertussis patient and shows a characteristic pattern of cough he/
she may be suspected to have pertussis. Bacterial identification 
through culture study is the most accurate diagnosis method but 
the culture is quite a complicated process. Recently, the test based on 
polymerase chain reaction (PCR) is being used increasingly and it is 
known to show a positive rate 2-3 times higher than that of culture 
study in typical cases
23-25). In a serologic test, the increase of pertussis 
antibody should be proved in serial serum at the acute stage and the 
convalescent stage. 
Immunization
1. Current state and background of development
The introduction of Tdap is required in order to decrease the 
incidence of pertussis in adolescents and adults, to prevent its spread 
from the older age groups to infants and toddlers, and to maintain 
herd immunity. It was found that around 76-83% of infant pertussis 
were from adolescents or adults with waning immunity against 
pertussis. In both natural infection and immunization, the immunity 
is not maintained lifelong, so adolescents and adults need to be 
vaccinated for the maintenance of immunity and now vaccination 
is available for this age group. In the U.S., two Tdap products for 
adolescents and adults were approved in 2005 and are being used 
(Table 1). 
These vaccines are similar to Td in terms of the contents of 
diphtheria and tetanus toxoid, but their content of pertussis vaccine is 
similar to or reduced to 1/3-1/4 of that of infant DTaP. ADACEL
TM 
(Sanofi-Pasteur) is a 5-component pertussis vaccine, which reduces 
the pertussis toxin (PT) content to 1/4 from that of DTaP by the same 
manufacturer but has the contents of filamentous haemagglutinin 
(FHA), pertactin, and fimbriae 2 and 3 as a same dose, and was 
approved for those aged between 11-64. BOOSTRIX
Ⓡ (GSK) 
is a 3-component pertussis vaccine, which reduces 3 pertussis 
components uniformly to 1/3 among the components of DTaP by 
the same manufacturer, and was approved for those aged between 10-
18 but the applicable age group was expanded recently up to 64 years. 
In Korea, both of the two products were approved for the prevention 
of diphtheria, tetanus and pertussis in adolescents and adults aged 
between 11-64.
2. Immunogenicity
 The Tdap products above were approved based on the results of 
clinical tests showing that they are not inferior to DTaP products of 
the respective manufacturers in terms of immunogenicity and safety. 
In clinical trials, the products were found to have immunogenicity 
and safety against diphtheria, tetanus and pertussis through single 
vaccination in adolescents. Tdap is administered once because single 
vaccination with Tdap is considered to induce an antibody response 
and clinical effect similar to those by three immunizations with 
DTaP in infants. 




PT FHA PRN FIM
Vaccines for children
INFANRIX
® GlaxoSmithKline 25 25 8 -
DAPTACEL
® Sanofi Pasteur 10   5 3 5
Vaccines for adolescents
BOOSTRIX
® GlaxoSmithKline 8   8   2.5 -
ADACEL
TM Sanofi Pasteur 2.5   5 3 5
*Per recommended dose of 0.5 mL. 
PT, pertussis toxin; FHA, filamentous haemagglutinin; PRN, pertactin; FIM, 
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                                         3. Vaccination schedule
 In case adolescents at the age of 11-18 completed 5 DTaP 
immu  nization series during their infancy and childhood, they are 
vaccinated with Tdap instead of Td once as a booster vaccination 
against tetanus, diphtheria and pertussis, and the recommended age 
is 11-12 years. If adolescents at the age of 11-18 were vaccinated with 
Td but not with Tdap, it is recommended to be vaccinated with Tdap 
once for maintaining immunity against pertussis and to keep at least 
2 years’ interval between the vaccination with Td and that with Tdap. 
However, vaccination with Tdap may be made in a shorter interval 
in case the risk of pertussis is high (e.g. close contact with a pertussis 
patient, the prevalence of pertussis, close contact with young infants). 
 
4. Administration and dosage
The vaccine is administered via intramuscularly at a dose of 0.5 
mL, and the deltoid muscle is preferred. The vaccine is kept at 2-8℃. 
 
5. Simultaneous administration and interchangeability
Tdap administered during adolescence does not need to be from 
the same manufacturer as that of DTaP administered during infancy. 
If all vaccines corresponding to the indications are available in a visit, 
they can be injected simultaneously at different sites.
 
6. Adverse events
1) Local adverse events
(1) ADACEL
TM
 Local adverse events observed commonly are pain, edema and 
erythema, which were observed in 77.8%, 20.9%, and 20.8%, 
respectively. Severe pain, edema and erythema were observed in 1.5%, 
6.4% and 6.0%, respectively. These adverse events are expected to be 
minimized using an appropriate administration method. 
(2) BOOSTRIX
Ⓡ
Local adverse events observed commonly are pain, edema and 
erythema, which were observed in 75.3%, 21.1% and 22.5%, 
respectively. Severe pain, edema and erythema were observed in 4.6%, 
2.5% and 1.7%, respectively. 
2) Systemic adverse events
(1)  ADACEL
TM
 Systemic adverse events such as fever, headache and fatigue were 
observed in 5.0%, 43.7% and 30.2%, respectively, and adverse events 
such as nausea, vomiting, diarrhea and arthralgia were also observed. 
Fever of over 39.0℃, severe headache and fatigue were observed in 
0.2%, 2.0% and 1.2%, respectively. 
(2) BOOSTRIX
Ⓡ
Systemic adverse events such as fever, headache and fatigue 
were observed in 13.5%, 43.1% and 37.0%, respectively, and 
gastrointestinal symptoms were observed in 26.0%. Fever of over 
39.0℃, severe headache and fatigue were observed in 1.4%, 3.7% and 
3.7%, respectively. 
3) Severe adverse events
(1) ADACEL
TM
Severe adverse events within 6 months from the vaccination were 




Severe abnormal responses within 6 months from the vaccination 
were observed in 0.4%, but they were reported not to be associated 
with the vaccine. 
 
7. Contraindications and Precautions
A serious allergic reaction (e.g. anaphylactic reaction) to the 
components of vaccine is a contraindication. If encephalopathy of 
unknown cause happened within 7 days from vaccination with 
vaccine containing pertussis components, it is a contraindication and 
in such a case Td should be administered. 
In case Guillain-Barre syndrome occurred within 6 weeks 
after receipt of a tetanus toxoid-containing vaccine in the past, the 
vaccination should be decided in consideration of risk and benefit. 
When the subject is under progressive neurologic disorder, the 
vaccination containing pertussis antigen should be delayed until the 
disorder is stabilized. 
 
8. Special situations
1) Tetanus prophylaxis indicated for wound management
Should receive Tdap (if not previously given) instead of Td.
2) Lack of availability of Tdap
Should receive Td when Tdap is indicated but not available if the 
last DTP/DTaP/Td was administered at least 10 y previously. If 
vaccine was administered less than 10 y previously, immunization 
can be deferred temporarily if follow-up is likely.
3) The subject has a history of pertussis
 Should receive Tdap
4) History of receipt of Td but incomplete pertussis immu-
nization
Should receive catch-up dose of Tdap; a 2 year interval generally is 
used
5) History of no DTP/DTaP/DT or Td immunization
Should receive catch-up doses of 3 Td-containing vaccines, one of 
which is Tdap
6) History of receipt of DTP/DTaP/DT or Td but incomplete 
record
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trations are 0.1 IU/ml or greater, presume previous immunization 
and administer a single dose of Tdap (to be considered the adolescent 
booster dose) 
7) Pregnancy
Pregnancy is not a contraindication to Tdap immunization. But, it 
should only be given if clinically indicated. 
8) Postpartum 
Mothers of newborn infants should be given a dose of Tdap as soon 
as is feasible if they previously have not received Tdap. 
9) Children 7 through 10 year of age with history of 
incomplete childhood DTP/DTaP immunization
Those not fully vaccinated against pertussis and for whom no 
contraindication to pertussis vaccine exists should receive a single 
dose of Tdap. Those never vaccinated against tetanus, diphtheria, or 
pertussis or who have unknown vaccination status should receive a 
series of three vaccination containing tetanus and diphtheria toxoids. 
The first of these three doses should be Tdap.
Future prospect
Along with the use of Tdap, related research should be made 
continuously. It is necessary to monitor the effect and safety of 
vaccination, and additional studies should be conducted on change in 
the epidemiology of pertussis in response to vaccination in Korea. 
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